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Advisory Com m ittee on Im m unization Practices (ACIP) 
Recom m ended Im m unization Schedules for Persons 
Aged 0 Through 18 years and Adults Aged 19 Years and Older —  
United States, 2013
Introduction
Each year, recommendations for routine use of vaccines 
in children, adolescents, and adults in the United States are 
developed by the Advisory Com m ittee on Im m unization 
Practices (ACIP). This year, for the first time, recommended 
immunization schedules for persons aged 0 through 18 years 
and adults aged 19 years and older are being published together.
Placing These Schedules on 
Your Website
C D C ’s National Center for Immunization and Respiratory 
Diseases (NCIRD) maintains the most current immunization 
schedules on the Vaccines and Im m unizations pages of 
C D C ’s website (http://www.cdc.gov/vaccines/schedules), 
including the schedules published in this supplement. If 
errors or omissions are discovered after publication of the 
schedules, C D C  posts revised versions on the Vaccines and 
Immunizations Web pages.
C D C  encourages organizations that have previously relied 
on copying and posting PDFs of the schedules to their websites 
to instead use a safer method to consistently display current 
schedules. This form of “content syndication” ensures that the 
most current and accurate immunization schedule information 
is on each organization’s website. This one-time step assures 
that your website displays current yearly schedules as soon as 
they are published, or revised.
To place the schedules on a website, organizations simply 
include two lines of CDC-furnished computer code on their 
Web page. Each organization’s Web developer places the code 
into their existing website; the code automatically loads the 
current C D C  schedule and footnotes. The schedule is visible 
within the organization’s Web page, and all other images and 
Web navigation display unchanged. Any C D C  revisions or
updates will automatically and immediately be reflected on 
the organization’s Web page.
This form of content syndication also gives organizations 
the ability to offer a PDF of each schedule on their website. 
Staff members and Web visitors can print as well as view 
im m unization schedules and be confident they have the 
most current versions. Instructions for copying and placing 
syndication code are available at http://www.cdc.gov/vaccines/ 
schedules/syndicate.html.
CDC offers technical assistance for organizations implementing 
this form of content syndication. For assistance, readers can 
complete the e-mail form on the NCIRD Web support page 
(http://www.cdc.gov/vaccines/web-support.html), and a NCIRD 
Web team staff member will contact them and provide assistance.
ACIP is chartered as a federal advisory committee to 
provide expert external advice and guidance to the Director 
of the Centers for Disease Control and Prevention (CDC) 
on use o f vaccines and related agents for the control of 
vaccine-preventable diseases in the civilian population 
of the United States. Recommendations for routine use 
of vaccines in children and adolescents are harmonized 
to the greatest extent possible with recommendations 
made by the American Academy o f Pediatrics (AAP), the 
American Academy of Family Physicians (AAFP), and the 
American College of Obstetricians and Gynecologists. 
Recommendations for routine use o f vaccines in adults 
are reviewed and approved by the American College 
o f Physicians (ACP), AAFP, the American College of 
Obstetricians and Gynecologists, and the American 
College o f Nurse-Midwives. ACIP recommendations 
adopted by the C D C  Director become agency guidelines 
on the date published in the M orbidity and Mortality 
Weekly Report {MMWR).
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Each year, the Advisory Committee on Immunization Practices 
(ACIP) reviews the current recommended immunization 
schedules for persons aged 0 through 18 years to ensure that 
the schedule reflects current recommendations for licensed 
vaccines. In October 2012, ACIP approved the recommended 
immunization schedules for persons aged 0 through 18 years for 
2013, which includes several changes from 2012.
Health-care providers are advised to use both the recommended 
schedule and the catch-up schedule (Figures 1 and 2) in 
combination with their footnotes (pages 6—8) and not as 
stand-alones. For guidance on the use o f all the vaccines in 
the schedules, including contraindications and precautions to 
use o f a vaccine, providers are referred to the respective ACIP 
vaccine recommendations.
Printable versions of the regular and catch-up schedules are 
available at http://www.cdc.gov/vaccines/schedules in various 
formats, including landscape and pocket-sized, in regular paper 
or laminated versions. A “parent friendly” regular schedule is 
available at http://www.cdc.gov/vaccines/schedules/easy-to- 
read/child.html#print.
For 2013, several new references and links to additional 
information have been added, including one for travel vaccine 
requirements and recommendations (1). New references also 
are provided for vaccination o f persons with primary and 
secondary immunodeficiencies. Changes to the previous 
schedules (2) include the following:
• Figure 1, “Recommended immunization schedule for 
persons aged 0 through 18 years” replaces 
“Recommended immunization schedule for persons aged 
0 through 6 years” and “Recommended immunization 
schedule for persons aged 7 through 18 years.”
— Wording was added to bars to represent the respective 
vaccine dose numbers in the series.
— The meningococcal conjugate vaccine (MCV4) purple 
bar was extended to age 6 weeks, to reflect licensure of 
Hib-MenCY vaccine.
— The hepatitis A (HepA) vaccine yellow bar was extended to 
better reflect routine age recommendations for use of HepA 
vaccine. New green and purple bars were added to reflect 
hepatitis A vaccine recommendations for older children.
— Abbreviations for influenza vaccine were updated with 
the an ticipation  o f quadrivalent vaccine for the 
2013—14 influenza season.
— Pneumococcal polysaccharide vaccine (PPSV23) was 
added to Figure 1.
• Footnotes were combined and standardized formatting 
was used to provide recommendations for each vaccine 
related to routine vaccination, catch-up vaccination, and 
vaccination of persons with high-risk medical conditions 
or under special circumstances.
— Meningococcal conjugate vaccine (MCV4) footnotes 
were updated to reflect recent recommendations (3).
— Tetanus and diphtheria toxoids and acellular pertussis 
(Tdap) vaccine footnotes were updated to reflect 
recent recommendations (4).
— Influenza vaccine footnotes were updated to provide dosing 
guidance for children aged 6 months through 8 years for 
the 2012—13 and 2013—14 influenza seasons (5).
• Meningococcal conjugate (MCV4) vaccine minimum ages 
and intervals were updated in Figure 2, “C atch-up 
immunization schedule for persons aged 4 months through 
18 years who start late or who are more than 1 month 
behind— United States, 2013,” to reflect licensure of Hib- 
MenCY vaccine.
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FIGURE 1. Recommended immunization schedule for persons aged 0 through 18 years — 2013 (for those who fall behind or start late, see the 
catch-up schedule [Figure 2])
These recommendationsmu st be read with the footnotes that foilow. For those whofall behind or start late, provide catch-up va ccination at the earliest 
opportunity as indica ted by the greet bars in Figure 1. To determine minimum intesvals between doses,see the catch-up schedule (Figute 2). School entry and 



















































^ Uô ^ Uoæ^” ^ Uosê
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This schedule includes recommendations in effect as of January 1, 2013. Any dose not administered at the recommended age should be administered at a subsequent visit, 
when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers 
should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at http://www.cdc.gov/ 
vaccines/pubs/acip-list.htm. Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online 
(http://www.vaers.hhs.gov) or by telephone (800-822-7967). Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. 
Additional information, including precautions and contraindications for vaccination, is available from CDC online (http://www.cdc.gov/vaccines) or by telephone 
(8OO-CDC-INFO [800-232-4636]).
This schedule is approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/vaccines/acip/index.html), the American Academy of Pediatrics (http:// 
www.aap.org), the American Academy of Family Physicians (http://www.aafp.org), and the American College of Obstetricians and Gynecologists (http://www.acog.org).
NOTE: The above recommendations must be read along w ith the footnotes on pages 6-8.
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FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind 
— United States, 2013
The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have? been delayed. A vaccine series does 
not need to be restarted, regfrdl ess o fthe  time that has elapsed between doces. Use the sectior appropriate for thechild'sage. Alwcys use this table in conjuni- 
tion wieh Figure 1 and the footnotes that follow.





Minimum Interval Between Doses
Dose 
1 to  dose 2
Dose 
2 to  dose 3
Dose 
3 to Vose 4
Dose 
4 to  dose 5
Hepatitis B1 Birth 4 weeks
8 weeks
and at least 16 weeks after first dose; 
minimum age for the final dose is 24 weeks
Rotavirus2 6 weeks 4 weeks 4 weeks2
Diphtheria, tetanus, 
pertussis3 6 weeks 4 weeks 4 weeks 6 months 6 months3
Haemophilus influenzae 
type b5 6 weeks
4 weeks
if first dose administered at younger than 
age 12 months 
8 weeks (as final dose) 
if first dose administered at age 12-14 months 
No further doses needed 
if first dose administered at age 15 months 
or older
4 weeks5
if current age is younger than 12 months 
8 weeks (as final dose)5 
if current age is 12 months or older and first 
dose administered at younger than age 12 
months and second dose administered at 
younger than 15 months 
No further doses needed 
ifprevious dose administered at age 15 months 
or older
8 weeks (as final 
Vose)
This Vose only 
necessary fot 
chilVtec aeeV 12 
th rouef 59 months 
oho  receiveV 




if first dose administered at younger than 
age 12 months 
8 weeks (as final dose for healthy children) 
if first dose administered at age 12 months or 
older or current age 24 through 59 months 
No further doses needed 
for healthy children if first dose administered at 
age 24 months or older
4 weeks
if current age is younger than 12 months 
8 weeks (as final dose for healthy children) 
if current age is 12 months or older 
No further doses needed 
for healthy children if previous dose 
administered at 
age 24 months or older
8 oeeks (as final 
Vose)
This Vose only 
necessary for 
aeeV 12 
throueh 59 months 
o ho  receiveV 
3 Voses before aee 
12 months or for 
chilVrec at hieh 
risk oho  receiveV 
3 Voses at any aee
Inactivated poliovirus7 6 weeks 4 weeks 4 weeks
6 months7 
minimum aee 4 
years for final Vose
Meningococcal13 6 weeks 8 weeks13 see footnote 13 see footnote 13
Measles, mumps, rubella9 12 months 4 weeks
Varicella10 12 months 3 months
Hepatitis A11 12 months 6 months
Persons aged 7 through 18 years
Tetanus, diphtheria; teta­
nus, diphtheria, pertussis4 7 years4 4 weeks
4 weeks
iffirst dose administered at younger than 
age 12 months 
6 months
if first dose administered at 12 months 
or older
6 months 




Human papillomavirus12 9 years Routine dosing intervals are recommended12
Hepatitis A11 12 months 6 months
Hepatitis B1 Birth 4 weeks 8 weeks(and at least 16 weeks after first dose)
Inactivated poliovirus7 6 weeks 4 weeks 4 weeks7 6 months7
Meningococcal13 6 weeks 8 weeks13
Measles, mumps, rubella9 12 months 4 weeks
Varicella10 12 months
3 months
if person is younger than age 13 years
4 weeks
if person is aged 13 years or older
NOTE: The above recommendations must be read along w ith the footnotes on pages 6-8.
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Footnotes: Recommended Immunization Schedule for Persons Aged 0 Through 18 Years — United States, 2013
Additional guidance for use of the vaccines described in this publication is available at http://www.cdc.gov/vaccines/pubs/acip-list.htm
1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
Routine vaccination:
At birth
• Administer monovalent HepB vaccine to all newborns before hospital 
discharge.
• For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, 
administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) 
within 12 hours of birth. These infants should be tested for HBsAg and 
antibody to HBsAg (anti-HBs) 1 to 2 months after completion of the HepB 
series, at age 9 through 18 months (preferably at the next well-child visit).
• If mother's HBsAg status is unknown, within 12 hours o f birth administer 
HepB vaccine to all infants regardless o f birth weight. For infants weigh­
ing <2,000 grams, administer HBIG in addition to HepB within 12 hours of 
birth. Determine mother's HBsAg status as soon as possible and, if she is 
HBsAg-positive, also administer HBIG for infants weighing >2,000 grams 
(no later than age 1 week).
Doses following the birth dose
• The second dose should be administered at age 1 or 2 months. Monovalent 
HepB vaccine should be used for doses administered before age 6 weeks.
• Infants who did not receive a birth dose should receive 3 doses of a HepB- 
containing vaccine on a schedule of 0, 1 to 2 months, and 6 months starting 
as soon as feasible. See Figure 2.
• The minimum interval between dose 1 and dose 2 is 4 weeks and between 
dose 2 and 3 is 8 weeks. The final (third or fourth) dose in the HepB vaccine 
series should be administered no earlier than age 24 weeks, and at least 
16 weeks after the first dose.
• Administration of a total o f 4 doses o f HepB vaccine is recommended 
when a combination vaccine containing HepB is administered after the 
birth dose.
Catch-up vaccination:
• Unvaccinated persons should complete a 3-dose series.
• A 2-dose series (doses separated by at least 4 months) o f adult formulation 
Recombivax HB is licensed for use in children aged 11 through 15 years.
• For other catch-up issues, see Figure 2.
2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV-1 [Rotarix]
and RV-5 [RotaTeq]).
Routine vaccination:
• Administer a series of RV vaccine to all infants as follows:
1. If RV-1 is used, administer a 2-dose series at 2 and 4 months of age.
2. If RV-5 is used, administer a 3-dose series at ages 2, 4, and 6 months.
3. If any dose in series was RV-5 or vaccine product is unknown for any 
dose in the series, a total o f 3 doses of RV vaccine should be administered.
Catch-up vaccination:
• The maximum age for the first dose in the series is 14 weeks, 6 days.
• Vaccination should not be initiated for infants aged 15 weeks 0 days 
or older.
• The maximum age for the final dose in the series is 8 months, 0 days.
• If RV-1(Rotarix) is administered for the first and second doses, a third dose 
is not indicated.
• For other catch-up issues, see Figure 2.
3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine.
(Minimum age: 6 weeks)
Routine vaccination:
• Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15-18 months, 
and 4 through 6 years. The fourth dose may be administered as early as age 
12 months, provided at least 6 months have elapsed since the third dose.
Catch-up vaccination:
• The fifth (booster) dose o f DTaP vaccine is not necessary if the fourth dose 
was administered at age 4 years or older.
• For other catch-up issues, see Figure 2.
4. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine.
(Minimum age: 10 years for Boostrix, 11 years for Adacel).
Routine vaccination:
• Administer 1 dose ofTdap vaccine to all adolescents aged 11 through 12 years.
• Tdap can be administered regardless of the interval since the last tetanus 
and diphtheria toxoid-containing vaccine.
• Administer one dose of Tdap vaccine to pregnant adolescents during each 
pregnancy (preferred during 27 through 36 weeks gestation) regardless 
of number o f years from prior Td or Tdap vaccination.
Catch-up vaccination:
• Persons aged 7 through 10 years who are not fully immunized with the 
childhood DTaP vaccine series, should receive Tdap vaccine as the first dose 
in the catch-up series; if additional doses are needed, use Td vaccine. For 
these children, an adolescent Tdap vaccine should not be given.
• Persons aged 11 through 18 years who have not received Tdap vaccine 
should receive a dose followed by tetanus and diphtheria toxoids (Td) 
booster doses every 10 years thereafter.
• An inadvertent dose of DTaP vaccine administered to children aged 7 
through 10 years can count as part o f the catch-up series. This dose can 
count as the adolescent Tdap dose, or the child can later receive a Tdap 
booster dose at age 11-12 years.
• For other catch-up issues, see Figure 2.
5. Haemophilus influenzae type b (Hib) conjugate vaccine. (Minimum age:
6 weeks)
Routine vaccination:
• Administer a Hib vaccine primary series and a booster dose to all infants. 
The primary series doses should be administered at 2, 4, and 6 months of 
age; however, if PRP-OMP (PedvaxHib or Comvax) is administered at 2 and 
4 months of age, a dose at age 6 months is not indicated. One booster dose 
should be administered at age 12 through15 months.
• Hiberix (PRP-T) should only be used for the booster (final) dose in children 
aged 12 months through 4 years, who have received at least 1 dose of Hib.
Catch-up vaccination:
• If dose 1 was administered at ages 12-14 months, administer booster (as 
final dose) at least 8 weeks after dose 1.
• If the first 2 doses were PRP-OMP (PedvaxHIB or Comvax), and were admin­
istered at age 11 months or younger, the third (and final) dose should be 
administered at age 12 through 15 months and at least 8 weeks after the 
second dose.
• If the first dose was administered at age 7 through 11 months, administer 
the second dose at least 4 weeks later and a final dose at age 12 through 15 
months, regardless of Hib vaccine (PRP-T or PRP-OMP) used for first dose.
• For unvaccinated children aged 15 months or older, administer only 1 dose.
• For other catch-up issues, see Figure 2.
Vaccination of persons with high-risk conditions:
• Hib vaccine is not routinely recommended for patients older than 5 years 
o f age. However one dose o f Hib vaccine should be administered to unvac­
cinated or partially vaccinated persons aged 5 years or older who have 
leukemia, malignant neoplasms, anatomic or functional asplenia (including 
sickle cell disease), human immunodeficiency virus (HIV) infection, or other 
immunocompromising conditions.
6a. Pneumococcal conjugate vaccine (PCV). (Minimum age: 6 weeks)
Routine vaccination:
• Administer a series of PCV13 vaccine at ages 2, 4, 6 months with a booster 
at age 12 through 15 months.
• For children aged 14 through 59 months who have received an age- 
appropriate series of 7-valent PCV (PCV7), administer a single supplemental 
dose o f 13-valent PCV (PCV13).
Catch-up vaccination:
• Administer 1 dose of PCV13 to all healthy children aged 24 through 59 
months who are not completely vaccinated for their age.
• For other catch-up issues, see Figure 2.
Vaccination of persons with high-risk conditions:
• For children aged 24 through 71 months with certain underlying medical 
conditions (see footnote 6c), administer 1 dose o f PCV13 if 3 doses of PCV 
were received previously, or administer 2 doses of PCV13 at least 8 weeks 
apart if fewer than 3 doses o f PCV were received previously.
• A single dose of PCV13 may be administered to previously unvaccinated 
children aged 6 through 18 years who have anatomic or functional asplenia 
(including sickle cell disease), HIV infection or an immunocompromising 
condition, cochlear implant or cerebrospinal fluid leak. See MMWR 2010;59 
(No. RR-11), available at http://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf.
• Administer PPSV23 at least 8 weeks after the last dose of PCV to children 
aged 2 years or older w ith certain underlying medical conditions (see 
footnotes 6b and 6c).
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Please note: An erratum has been published for this issue. To view the erratum, please click here.
6b. Pneumococcal polysaccharide vaccine (PPSV23). (Minimum age: 2 years) 
Vaccination of persons with high-risk conditions:
• Administer PPSV23 at least 8 weeks after the last dose o f PCV to children 
aged 2 years or older w ith certain underlying medical conditions (see 
footnote 6c). A single revaccination with PPSV should be administered 
after 5 years to children with anatomic or functional asplenia (including 
sickle cell disease) or an immunocompromising condition.
6c. Medical conditions for which PPSV23 is indicated in children aged 2 
years and older and for which use of PCV13 is indicated in children 
aged 24 through 71 months:
• Immunocompetent children with chronic heart disease (particularly cya­
notic congenital heart disease and cardiac failure); chronic lung disease 
(including asthma if treated with high-dose oral corticosteroid therapy), 
diabetes mellitus; cerebrospinal fluid leaks; or cochlear implant.
• Children with anatomic or functional asplenia (including sickle cell disease 
and other hemoglobinopathies, congenital or acquired asplenia, or splenic 
dysfunction);
• Children with immunocompromising conditions: HIV infection, chronic 
renal failure and nephrotic syndrome, diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, including malignant 
neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ 
transplantation, congenital immunodeficiency.
7. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
Routine vaccination:
• Administer a series o f IPV at ages 2, 4, 6-18 months, with a booster at age 
4-6  years. The final dose in the series should be administered on or after 
the fourth birthday and at least 6 months after the previous dose.
Catch-up vaccination:
• In the first 6 months o f life, minimum age and minimum intervals are only 
recommended if the person is at risk for imminent exposure to circulating 
poliovirus (i.e., travel to a polio-endemic region or during an outbreak).
• If 4 or more doses are administered before age 4 years, an additional dose 
should be administered at age 4 through 6 years.
• A fourth dose is not necessary if the third dose was administered at age 4 
years or older and at least 6 months after the previous dose.
• If both OPV and IPV were administered as part o f a series, a total o f 4 doses 
should be administered, regardless o f the child's current age.
• IPV is not routinely recommended for U.S. residents aged 18 years or older.
• For other catch-up issues, see Figure 2.
8. Influenza vaccines. (Minimum age: 6 months for inactivated influenza 
vaccine [IIV]; 2 years for live, attenuated influenza vaccine [LAIV]) 
Routine vaccination:
• Administer influenza vaccine annually to all children beginning at age 6 
months. For most healthy, nonpregnant persons aged 2 through 49 years, 
either LAIV or IIV may be used. However, LAIV should NOT be administered 
to some persons, including 1) those with asthma, 2) children 2 through 4 
years who had wheezing in the past 12 months, or 3) those who have any 
other underlying medical conditions that predispose them to influenza 
complications. For all other contraindications to use of LAIV see MMWR 2010; 
59 (No. RR-8), available at http://www.cdc.gov/mmwr/pdf/rr/rr5908.pdf.
• Administer 1 dose to persons aged 9 years and older.
For children aged 6 months through 8 years:
• For the 2012-13 season, administer 2 doses (separated by at least 4 weeks) 
to children who are receiving influenza vaccine for the first time. For 
additional guidance, follow dosing guidelines in the 2012 ACIP influenza 
vaccine recommendations, MMWR 2012; 61: 613-618, available at http :// 
www.cdc.gov/mmwr/pdf/wk/mm6132.pdf.
• For the 2013-14 season, follow dosing guidelines in the 2013 ACIP influenza 
vaccine recommendations.
9. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12 months 
for routine vaccination)
Routine vaccination:
• Administer the first dose of MMR vaccine at age 12 through 15 months, 
and the second dose at age 4 through 6 years. The second dose may be 
administered before age 4 years, provided at least 4 weeks have elapsed 
since the first dose.
• Administer 1 dose of MMR vaccine to infants aged 6 through 11 months 
before departure from the United States for international travel. These 
children should be revaccinated with 2 doses of MMR vaccine, the first 
at age 12 through 15 months (12 months if the child remains in an area 
where disease risk is high), and the second dose at least 4 weeks later.
• Administer 2 doses o f MMR vaccine to children aged 12 months and older, 
before departure from the United States for international travel. The first 
dose should be administered on or after age 12 months and the second 
dose at least 4 weeks later.
Catch-up vaccination:
• Ensure that all school-aged children and adolescents have had 2 doses of 
MMR vaccine; the minimum interval between the 2 doses is 4 weeks.
10. Varicella (VAR) vaccine. (Minimum age: 12 months)
Routine vaccination:
• Administer the first dose o f VAR vaccine at age 12 through 15 months, 
and the second dose at age 4 through 6 years. The second dose may be 
administered before age 4 years, provided at least 3 months have elapsed 
since the first dose. If the second dose was administered at least 4 weeks 
after the first dose, it can be accepted as valid.
Catch-up vaccination:
• Ensure that all persons aged 7 through 18 years w ithout evidence of 
immunity (see MMWR 2007;56 [No. RR-4], available at http://www.cdc.gov/ 
mmwr/pdf/rr/rr5604.pdf) have 2 doses of varicella vaccine. For children 
aged 7 through 12 years the recommended minimum interval between 
doses is 3 months (if the second dose was administered at least 4 weeks 
after the first dose, it can be accepted as valid); for persons aged 13 years 
and older, the minimum interval between doses is 4 weeks.
11. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
Routine vaccination:
• Initiate the 2-dose HepA vaccine series for children aged 12 through 23 
months; separate the 2 doses by 6 to 18 months.
• Children who have received 1 dose of HepA vaccine before age 24 months, 
should receive a second dose 6 to 18 months after the first dose.
• For any person aged 2 years and older who has not already received the HepA 
vaccine series, 2 doses of HepA vaccine separated by 6 to 18 months may 
be administered if immunity against hepatitis A virus infection is desired.
Catch-up vaccination:
• The minimum interval between the two doses is 6 months.
Special populations:
• Administer 2 doses of Hep A vaccine at least 6 months apart to previously 
unvaccinated persons who live in areas where vaccination programs target 
older children, or who are at increased risk for infection.
12. Human papillomavirus (HPV) vaccines. (HPV4 [Gardasil] and HPV2
[Cervarix]). (Minimum age: 9 years)
Routine vaccination:
• Administer a 3-dose series of HPV vaccine on a schedule of 0, 1-2, and 6 
months to all adolescents aged 11-12 years. Either HPV4 or HPV2 may be 
used for females, and only HPV4 may be used for males.
• The vaccine series can be started beginning at age 9 years.
• Administer the second dose 1 to 2 months after the first dose and the third 
dose 6 months after the first dose (at least 24 weeks after the first dose).
Catch-up vaccination:
• Administer the vaccine series to females (either HPV2 or HPV4) and males 
(HPV4) at age 13 through 18 years if not previously vaccinated.
• Use recommended routine dosing intervals (see above) for vaccine series 
catch-up.
13. Meningococcal conjugate vaccines (MCV). (Minimum age: 6 weeks
for Hib-MenCY, 9 months for Menactra [MCV4-D], 2 years for Menveo
[MCV4-CRM]).
Routine vaccination:
• Administer MCV4 vaccine at age 11-12 years, with a booster dose at age 
16 years.
• Adolescents aged 11 through 18 years with human immunodeficiency 
virus (HIV) infection should receive a 2-dose primary series of MCV4, with 
at least 8 weeks between doses. See MMWR 2011; 60:1018-1019 available 
at: http://www.cdc.gov/mmwr/pdf/wk/mm6030.pdf.
• For children aged 9 months through 10 years with high-risk conditions, 
see below.
Catch-up vaccination:
• Administer MCV4 vaccine at age 13 through 18 years if not previously 
vaccinated.
• If the first dose is administered at age 13 through 15 years, a booster dose 
should be administered at age 16 through 18 years with a minimum interval 
o f at least 8 weeks between doses.
• If the first dose is administered at age 16 years or older, a booster dose is 
not needed.
• For other catch-up issues, see Figure 2.
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Vaccination of persons with high-risk conditions:
• For children younger than 19 months o f age with anatomic or functional 
asplenia (including sickle cell disease), administer an infant series of Hib- 
MenCY at 2, 4, 6, and 12-15 months.
• For children aged 2 through 18 months w ith persistent complement 
component deficiency, administer either an infant series of Hib-MenCY at 
2, 4, 6, and 12 through 15 months or a 2-dose primary series of MCV4-D 
starting at 9 months, with at least 8 weeks between doses. For children 
aged 19 through 23 months w ith persistent complement component 
deficiency who have not received a complete series o f Hib-MenCY or 
MCV4-D, administer 2 primary doses o f MCV4-D at least 8 weeks apart.
• For children aged 24 months and older w ith persistent complement 
component deficiency or anatomic or functional asplenia (including sickle 
cell disease), who have not received a complete series of Hib-MenCY or 
MCV4-D, administer 2 primary doses of either MCV4-D or MCV4-CRM. If
MCV4-D (Menactra) is administered to a child with asplenia (including sickle 
cell disease), do not administer MCV4-D until 2 years of age and at least 4 
weeks after the completion of all PCV13 doses. See MMWR 2011;60:1391-2, 
available at http://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf.
• For children aged 9 months and older who are residents of or travelers to 
countries in the African meningitis belt or to the Hajj, administer an age 
appropriate formulation and series of MCV4 for protection against sero­
groups A and W-135. Prior receipt o f Hib-MenCY is not sufficient for children 
traveling to the meningitis belt or the Hajj. See MMWR 2011;60:1391-2, 
available at http://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf.
• For children who are present during outbreaks caused by a vaccine sero­
group, administer or complete an age and formulation-appropriate series 
o f Hib-MenCY or MCV4.
• For booster doses among persons with high-risk conditions refer to h ttp :// 
www.cdc.gov/vaccines/pubs/acip-list.htmtmening.
Additional Vaccine Information
For contraindications and precautions to use of a vaccine and for additional 
information regarding that vaccine, vaccination providers should consult 
the relevant ACIP statement available online at http://www.cdc.gov/ 
vaccines/pubs/acip-list.htm.
For the purposes of calculating intervals between doses, 4 weeks = 28 days. 
Intervals of 4 months or greater are determined by calendar months. 
Information on travel vaccine requirements and recommendations is 
available at http://wwwnc.cdc.gov/travel/page/vaccinations.htm.
For vaccination of persons with primary and secondary immunodeficiencies, 
see Table 13, "Vaccination o f persons w ith  primary and secondary 
immunodeficiencies,” in General Recommendations on Immunization 
(ACIP), available at h ttp ://w w w .cdc.gov/m m w r/preview /m m w rhtm l/ 
rr6002a1.htm; and American Academy of Pediatrics. Passive immunization. 
In: Pickering LK, Baker CJ, Kimberlin DW, Long SS eds. Red book: 2012 
report o f the Committee on Infectious Diseases. 29th ed. Elk Grove Village, 
IL: American Academy o f Pediatrics.
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Vaccines are recommended for adults on the basis o f age, 
prior vaccinations, health conditions, lifestyle, occupation, and 
travel. Current levels o f vaccination coverage among adults 
are low (1). Health-care providers should be aware of the 
importance of routinely assessing patients’ vaccination histories 
and recommending and providing routinely recommended 
vaccines. A strong recom m endation from a health-care 
provider is associated with increased uptake of vaccines (2,3). 
O ther interventions shown to increase vaccine uptake, such 
as implementation of reminder/recall systems and standing 
orders, have been summarized by the Com munity Guide (3).
The Advisory Committee on Immunization Practices (ACIP) 
annually reviews and updates the adult immunization schedule, 
which is designed to provide vaccine providers with a summary 
of existing ACIP recommendations regarding the routine use 
of vaccines for adults (Figures 1 and 2). The adult schedule also 
includes a table summarizing the primary contraindications and 
precautions for routinely recommended vaccines (Table). In 
October 2012, ACIP approved the adult immunization schedule 
for 2013. This schedule also incorporates changes to vaccine 
recommendations voted on by ACIP at its October 24—25, 
2012 meeting.
The primary updates include adding information for the first 
time on the use of 13-valent pneumococcal conjugate vaccine 
(PCV13) and the timing of administration ofPCV13 relative to 
the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in 
adults (4). PCV13 is recommended for adults aged 19 years and 
older with immunocompromising conditions (including chronic 
renal failure and nephrotic syndrome), functional or anatomic 
asplenia, cerebrospinal fluid leaks, or cochlear implants. The 
schedule also clarifies which adults need 1 or 2 doses of PPSV23 
before age 65 years. Other changes to the PPSV23 footnote 
include adding information regarding recommendations for 
vaccination when vaccination status is unknown.
For tetanus, diphtheria, and acellular pertussis (Tdap) 
vaccine, recommendations have been expanded to include 
routine vaccination of adults aged 65 years and older and for
pregnant women to receive Tdap vaccine with each pregnancy. 
The ideal timing of Tdap vaccination during pregnancy is 
during 27—36 weeks’ gestation. This recommendation was 
made to increase the likelihood of optimal protection for the 
pregnant woman and her infant during the first few months of 
the infant’s life, when the child is too young for vaccination but 
at highest risk for severe illness and death from pertussis (5,6).
Manufacturers o f the live, attenuated influenza vaccine 
(LAIV) have obtained Food and Drug Administration (FDA) 
approval for a quadrivalent influenza vaccine that contains 
one influenza A (H3N2), one influenza A (H1N1) and two 
influenza B vaccine virus strains, one from each lineage of 
circulating influenza B viruses. In approximately half of 
the recent influenza seasons, the trivalent influenza vaccine 
has included an influenza B vaccine virus from the lineage 
different from the predominant circulating influenza B strains
(7). Inclusion of both lineages of influenza B virus is intended 
to increase the likelihood that the vaccine provides cross­
reactive antibody against a higher proportion o f circulating 
influenza B viruses. For LAIV, beginning with the 2013—14 
season, it is expected that only the quadrivalent formulation 
will be available and manufacture of the trivalent formulation 
will cease. It is possible that quadrivalent inactivated influenza 
vaccine formulations might be available for the 2013—14 season 
as well. Because a mix of quadrivalent and trivalent influenza 
vaccines might be available in 2013—14, the abbreviation for 
inactivated influenza vaccine has been changed from trivalent 
inactivated influenza vaccine (TIV) to inactivated influenza 
vaccine (IIV). The abbreviation for LAIV remains unchanged.
M inor wording changes, clarifications, or simplifications 
have been made to footnotes for measles, mumps, rubella 
vaccine (MMR), human papillomavirus vaccine (HPV), zoster 
vaccine, and hepatitis A and hepatitis B vaccines. A correction 
has been made to Figure 1 for M M R  vaccine: the bar that 
indicated the vaccine might be used in certain situations by 
persons born before 1957 has been removed. Persons born 
before 1957 are considered immune, and routine vaccination
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is not recommended. Considerations for the possible use of 
M M R  vaccine in outbreak situations are included in the 2011 
M M W R  publication on vaccination of health-care personnel
(8). In addition, a correction was made to Figure 2 for PPSV23. 
This vaccine is indicated for men who have sex with men if they 
have another risk factor (e.g., age or underlying condition); the 
bar has been changed from yellow to purple to more accurately 
reflect the recommendation.
Vaccine providers are reminded to consult the full ACIP 
vaccine recommendations if they have questions and to bear 
in mind that additional updates might be made for specific 
vaccines during the year between updates to the adult schedule. 
Printable versions of the 2013 adult immunization schedule 
and other information is available at http://www.cdc.gov/ 
vaccines/schedules/hcp/adult.html. Information about adult 
vaccination is available at http://www.cdc.gov/vaccines/default. 
h tm . ACIP statements and information for specific vaccines 
is available at http://www.cdc.gov/vaccines/pubs/acip-list. 
h tm . Adverse events from vaccination should be reported at 
http://www.vaers.hhs.gov or by telephone, 800-822-7967. 
This schedule has been approved by the American Academy 
o f Family Physicians, the American College of Physicians, 
the American College o f Obstetricians and Gynecologists, 
and the American College o f Nurse-Midwives. The adult 
immunization schedule is published in the Annals o f Internal 
Medicine at the same time that it is published in M M W R .
Changes for 2013 
Footnotes
• Information was added to footnote #1 to direct readers 
to additional information regarding recommendations 
for vaccination when vaccination status is unknown.
• The influenza vaccination footnote (#2) now uses the 
abbreviation IIV for inactivated influenza vaccine and 
drops the abbreviation TIV  for trivalent inactivated 
vaccine (TIV). For the 2013—14 influenza season, it is 
expected that the LAIV will be available only in a 
quadrivalent formulation; IIV might be available in 
both trivalent and quadrivalent formulations.
• The tetanus, diphtheria, and acellular pertussis (Td/Tdap) 
vaccination footnote (#3) is updated to include the 
recommendation to vaccinate pregnant women with Tdap 
during each pregnancy, regardless of the interval since prior 
Td/Tdap vaccination and to include the recommendation 
for all other adults, including persons aged 65 years and 
older, to receive 1 dose of Tdap vaccine.
• The varicella (#4) and H PV  (#5) footnotes were 
simplified; no changes in recommendations were made. 
Additional information was added to the HPV  footnote 
regarding HPV vaccination and pregnancy.
• The zoster footnote (#6) was changed to clarify that 
ACIP recommends vaccination of persons beginning at 
age 60 years both for persons with and without 
underlying health conditions for whom the vaccine is 
not contraindicated.
• The measles, mumps, rubella (MMR) vaccine footnote 
(#7) was modified to reflect the new recommendation that 
a provider diagnosis of measles, mumps, or rubella is not 
considered acceptable evidence of immunity. Previously, a 
provider diagnosis of measles or mumps, but not rubella, 
was considered acceptable evidence of immunity.
• Information was added to the pneumococcal 
polysaccharide (PPSV23) vaccination footnote (#8) and 
PPSV23 revaccination footnote (#9) to clarify that 
persons with certain medical conditions are 
recommended to receive 2 doses of PPSV23 before age 
65 years. In addition, even those who receive 2 doses of 
PPSV23 before age 65 years are recommended to 
receive PPSV23 at age 65 years, as long as it has been 5 
years since the most recent dose. The PPSV23 footnote 
refers to footnote #10 for pneumococcal conjugate 
13-valent vaccine (PCV13) regarding the timing of 
PCV13 vaccine relative to PPSV23 for those persons 
recommended to be vaccinated with both 
pneumococcal vaccines.
• A new footnote (#10) was added for PCV13 vaccine. 
This vaccine is recommended for adults aged 19 years 
and older with immunocompromising conditions 
(including chronic renal failure and nephrotic 
syndrome), functional or anatomic asplenia, 
cerebrospinal fluid leaks, or cochlear implants. Those 
not previously vaccinated with PCV13 or PPSV23 
should receive a single dose of PCV13, followed by a 
dose of PPSV23 at least 8 weeks later. Those previously 
vaccinated with PPSV23 should be vaccinated with 
PCV13 one year or more after PPSV23 vaccination (4).
• The hepatitis A vaccine footnote (#12) was updated to 
clarify that vaccination is recommended for persons with a 
history of either injection or noninjection illicit drug use.
• The hepatitis B vaccine footnote (#13) includes minor 
wording changes and adds information on the vaccine 
schedule for hepatitis B vaccine series for the Recombivax 
HB vaccine. The dosing schedules for other hepatitis B 
vaccines were included in prior years’ schedules.
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Figures
• For figure 1, the bar for Tdap/Td for persons aged 65 
years and older has been changed to solid yellow because 
all adults, including those 65 years and older, are now 
recommended to receive one dose of Tdap vaccine (5).
• The bar for M M R vaccine for persons born before 1957 
has been removed. M M R vaccine is not recommended 
routinely for persons born before 1957. Considerations 
for vaccination in measles or mumps outbreak settings 
are discussed in the ACIP recommendations for health­
care personnel (8).
• A new row for PCV13 vaccine has been added.
• For Figure 2, the recommendation for Tdap vaccination 
with each pregnancy is included, with a single dose of 
Tdap recommended for all other groups (6).
• A correction was made to change the color for PPSV23 
from yellow to purple for men who have sex with men 
(MSM). PPSV23 is recommended for MSM who have 
another risk factor such as age group or medical condition.
• A row for PCV13 was added (4).
Contraindications and 
Precautions Table
• The inactivated influenza vaccine precautions were 
updated to indicate that persons who experience only 
hives with exposure to eggs should receive IIV rather 
than LAIV.
• Pregnancy was removed as a precaution for hepatitis A 
vaccine. This is an inactivated vaccine, and similar to 
hepatitis B vaccines, is recommended if another high 
risk condition or other indication is present.
• Language was clarified regarding the precaution for use 
o f antiviral medications and vaccination with varicella 
or zoster vaccines.
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These recommendations must be read with the footnotes that follow.
FIGURE 1. Recommended adult immunization schedule, by vaccine and age group1
VACCINE ▼ AGE GROUP ► 19-21 years 22-26 years 27-49 years 50-59 years 60-64 years > 65 years
In flu en za2* 1 dose a n n u a lly
Tetanus, diphtheria, pertussis (Td/Tdap) 3* S u b s titu te  1 -tim e  d ose  o f  Tdap  fo r  Td bo o ste r; th e n  bo o st w ith  Td e v e ry  1 0  yrs
Varicella 4* 2 doses
Human papillomavirus (HPV) Female 5* 3 doses
Human papillomavirus (HPV) Male 5* 3 do>ses
Zoster 6 1 d ose
Measles, mumps, rubella (MMR) 7* 1 o r 2 dos<:s
Pneumococcal polysaccharide (PPSV23) 8,9 1 or 2 doses 1 dose
Pneumococcal 13-valent conjugate (PCV13) 10 1 dose
Meningococcal n * 1 o r m o re  doses
Hepatitis A 12* 2 doses
Hepatitis B 13* 3 doses
*Covered by the Vaccine Injury Compensation Program
For all persons in this category who 
meet the age requirements and who lack 
documentation of vaccination or have no 
evidence of previous infection; 
zoster vaccine recommended regardless 
of prior episode of zoster
Recommended if some other risk factor 
is present (e.g., on the basis of medical, 
occupational, lifestyle, or other indication)
No recommendation
R eport all c lin ica lly  s ign ifican t postvacc ina tion  reactions to  th e  Vaccine Adverse Event R eporting  System (VAERS). R epo rting  fo rm s and ins truc tions  on 
filin g  a VAERS re p o rt are availab le  at w w w .vaers.hhs.gov o r by te le p h o n e , 800-822-7967.
In fo rm a tion  on h o w  to  file  a Vaccine In ju ry  C om pensation  Program  c la im  is ava ilab le  at w w w .h rsa .gov /vacc inecom pen sa tion  o r by te lephone , 
800-338-2382. To f i le  a c la im  fo r  vacc ine  in jury, co n ta c t th e  U.S. C ourt o f  Federal Claims, 717 M adison Place, N.W., W ash ing ton , D.C. 20005; te lephone , 
202-357-6400.
A d d itio n a l in fo rm a tio n  a b o u t th e  vaccines in th is  schedule, e x te n t o f  ava ilab le  data, and  co n tra ind ica tions  fo r vacc ina tion  is also ava ilab le  a t w w w .cd c . 
gov/vacc ines o r fro m  th e  CDC-INFO C ontact C enter a t 800-CDC-INFO (800-232-4636) in English and  Spanish, 8:00 a.m. - 8:00 p.m. Eastern T im e, M onday 
- Friday, exc lud ing  holidays.
Use o f  tra d e  nam es and com m erc ia l sources is fo r id e n tifica tio n  o n ly  and does n o t im p ly  end o rse m e n t by th e  U.S. D e p a rtm e n t o f H ea lth  and H um an 
Services.
The recommendations in this schedule were approved by the  Centers for Disease Control and Prevention's (CDC) Advisory Committee on 
Immunization Practices (ACIP), the American Academy of Family Physicians (AAFP), the American College of Physicians (ACP), American 
College of Obstetricians and Gynecologists and American College of Nurse-Midwives (ACNM).
FIGURE 2. Recommended vaccinations indicated for adults based on medical and other indications1
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Influenza ij* □ 1 d ose  IIV  a n n u a lly  | |1 dose IIV or LAIV 1 I annually I | 1 d ose  IIV  a n n u a lly |1 dose IIV or LAIV I 1 annually I
Tetanus, diphtheria, pertussis (Td/Tdap) 3 11 dose Tdap each 1 1 pregnancy 1 1 S u b s titu te  1 -t im e  dose «of T d a p  fo r  Td bo o ste r; th e n  bo o st w ith  Td e v e ry  1 0  yrs
Varicella 4* C o n tra in d ic a te d □ 2 doses |
Human papillomavirus (HPV) Female 5 | 3 doses th ro u g h  a g e  2 6  yrs  | | 3 doses th ro u g h  a g e  2 6  yrs  |
Human papillomavirus (HPV) Male 5 | 3 doses th ro u g h  a g e  2 6  yirs | | 3 doses th ro u g h  a g e  21 yrs  |
Zoster 6 <C o ntra ind icated 1 d ose  |
Measles, mumps, rubella (MMR) 7* C o n tra in d ic a te d □ 1 o r 2 doses |
Pneumococcal polysaccharide (PPSV23) 8,9 1 o r 2 doses
Pneumococcal 13-valent conjugate (PCV13) 10 1 dose
Meningococcal 11, □ 1 o r m o re  doses □
Hepatitis A 12* 2 doses
Hepatitis B 1!* 3 doses
*Covered by the Vaccine Injury Compensation Program
I I For all persons in this category who meet the age requirements and who lack
I-------------- 1 documentation of vaccination or have no evidence of previous infection;
zoster vaccine recommended regardless of prior episode of zoster 
I I Recommended if some other risk factor is present (e.g., on the basis of medical,
I-------------- 1 occupational, lifestyle, or other indications)
I I No recommendation
These schedu les in d ic a te  th e  re c o m m e n d e d  a ge  g ro u p s  and m ed ica l in d ica tio n s  fo r  w h ic h  a d m in is tra tio n  
o f  cu rre n tly  licensed vacc ines is c o m m o n ly  in d ica te d  fo r  a d u lts  ages 19 years and  o lder, as o f  January 1, 
2013. For all vacc ines b e in g  re c o m m e n d e d  on  th e  A d u lt Im m u n iz a tio n  Schedule: a vacc ine  series does 
no t need to  be res ta rted , regard less o f  th e  t im e  th a t has e lapsed b e tw e e n  doses. L icensed c o m b in a tio n  
vacc ines m ay be used w h e n e v e r any co m p o n e n ts  o f  th e  c o m b in a tio n  are in d ica te d  a nd  w h e n  th e  
vaccine 's o th e r co m p o n e n ts  are n o t co n tra in d ica te d . For d e ta ile d  re co m m e n d a tio n s  on  all vaccines, 
in c lu d in g  th o s e  used p r im a rily  fo r  trave le rs  o r th a t  are issued d u r in g  th e  year, co n s u lt th e  m a n u fa c tu re rs ' 
package inserts  and  th e  c o m p le te  s ta te m e n ts  fro m  th e  A d v iso ry  C o m m itte e  on  Im m u n iza tio n  
Practices (w w w .c d c .g o v /v a c c in e s /p u b s /a c ip - lis t.h tm ). Use o f  t ra d e  nam es and co m m e rc ia l sources is 
fo r  id e n tif ic a tio n  o n ly  and  does n o t im p ly  e n d o rs e m e n t by th e  U.S. D e p a rtm e n t o f  H ea lth  and  H um an 
Services.
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Footnotes: Recommended Immunization Schedule for Adults Aged 19 Years and Older — United States, 2013
1. Additional information
• Additional guidance for the use of the vaccines described in this supple­
ment is available at http://www.cdc.gov/vaccines/pubs/acip-list.htm.
• Information on vaccination recommendations when vaccination status is 
unknown and other general immunization information can be found in 
the General Recommendations on Immunization at http://www.cdc.gov/ 
mmwr/preview/mmwrhtml/rr6002a1.htm.
• Information on travel vaccine requirements and recommendations (e.g., 
for hepatitis A and B, meningococcal, and other vaccines) are available at 
http://wwwnc.cdc.gov/travel/page/vaccinations.htm.
2. Influenza vaccination
• Annual vaccination against influenza is recommended for all persons aged 
6 months and older.
• Persons aged 6 months and older, including pregnant women, can receive 
the inactivated influenza vaccine (IIV).
• Healthy, nonpregnant persons aged 2-49 years without high-risk medical 
conditions can receive either intranasally administered live, attenuated 
influenza vaccine (LAIV) (FluMist), or IIV. Health-care personnel who care 
for severely immunocompromised persons (i.e., those who require care in 
a protected environment) should receive IIV rather than LAIV.
• The intramuscularly or intradermally administered IIV are options for adults 
aged 18-64 years.
• Adults aged 65 years and older can receive the standard dose IIV or the 
high-dose IIV (Fluzone High-Dose).
3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
• Administer one dose of Tdap vaccine to pregnant women during each 
pregnancy (preferred during 27-36 weeks' gestation), regardless of number 
of years since prior Td or Tdap vaccination.
• Administer Tdap to all other adults who have not previously received 
Tdap or for whom vaccine status is unknown. Tdap can be administered 
regardless of interval since the most recent tetanus or diphtheria-toxoid 
containing vaccine.
• Adults with an unknown or incomplete history of completing a 3-dose 
primary vaccination series with Td-containing vaccines should begin or 
complete a primary vaccination series including a Tdap dose.
• For unvaccinated adults, administer the first 2 doses at least 4 weeks apart 
and the third dose 6-12 months after the second.
• For incompletely vaccinated (i.e., less than 3 doses) adults, administer 
remaining doses.
• Refer to the Advisory Committee on Immunization Practices (ACIP) state­
ment for recommendations for administering Td/Tdap as prophylaxis in 
wound management (see footnote #1).
4. Varicella vaccination
• All adults w ithout evidence of immunity to varicella (as defined below) 
should receive 2 doses of single-antigen varicella vaccine or a second dose 
if they have received only 1 dose.
• Special consideration for vaccination should be given to those who have 
close contact w ith persons at high risk for severe disease (e.g., health-care 
personnel and family contacts o f persons with immunocompromising 
conditions) or are at high risk for exposure or transmission (e.g., teachers; 
child care employees; residents and staff members of institutional settings, 
including correctional institutions; college students; military personnel; 
adolescents and adults living in households with children; nonpregnant 
women o f childbearing age; and international travelers).
• Pregnant women should be assessed for evidence of varicella immunity. 
Women who do not have evidence of immunity should receive the first 
dose of varicella vaccine upon completion or termination o f pregnancy 
and before discharge from the health-care facility. The second dose should 
be administered 4-8  weeks after the first dose.
• Evidence o f immunity to varicella in adults includes any of the following:
— documentation of 2 doses of varicella vaccine at least 4 weeks apart;
—  U.S.-born before 1980 except health-care personnel and pregnant 
women;
—  history o f varicella based on diagnosis or verification o f varicella 
disease by a health-care provider;
—  history of herpes zoster based on diagnosis or verification of herpes 
zoster disease by a health-care provider; or
—  laboratory evidence of immunity or laboratory confirmation of disease.
5. Human papillomavirus (HPV) vaccination
• Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and 
quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).
• For females, either HPV4 or HPV2 is recommended in a 3-dose series for 
routine vaccination at age 11 or 12 years, and for those aged 13 through 
26 years, if not previously vaccinated.
• For males, HPV4 is recommended in a 3-dose series for routine vaccination 
at age 11 or 12 years, and for those aged 13 through 21 years, if not previ­
ously vaccinated. Males aged 22 through 26 years may be vaccinated.
• HPV4 is recommended for men who have sex with men (MSM) through age 
26 years for those who did not get any or all doses when they were younger.
• Vaccination is recommended for immunocompromised persons (including 
those with HIV infection) through age 26 years for those who did not get 
any or all doses when they were younger.
• A complete series for either HPV4 or HPV2 consists o f 3 doses. The second 
dose should be administered 1-2 months after the first dose; the third dose 
should be administered 6 months after the first dose (at least 24 weeks 
after the first dose).
• HPV vaccines are not recommended for use in pregnant women. However, 
pregnancy testing is not needed before vaccination. If a woman is found 
to be pregnant after initiating the vaccination series, no intervention 
is needed; the remainder o f the 3-dose series should be delayed until 
completion o f pregnancy.
• Although HPV vaccination is not specifically recommended for health-care 
personnel (HCP) based on their occupation, HCP should receive the HPV 
vaccine as recommended (see above).
6. Zoster vaccination
• A single dose o f zoster vaccine is recommended for adults aged 60 years 
and older regardless of whether they report a prior episode of herpes zoster. 
Although the vaccine is licensed by the Food and Drug Administration 
(FDA) for use among and can be administered to persons aged 50 years 
and older, ACIP recommends that vaccination begins at age 60 years.
• Persons aged 60 years and older with chronic medical conditions may be 
vaccinated unless their condition constitutes a contraindication, such as 
pregnancy or severe immunodeficiency.
• Although zoster vaccination is not specifically recommended for HCP, they 
should receive the vaccine if they are in the recommended age group.
7. Measles, mumps, rubella (MMR) vaccination
• Adults born before 1957 generally are considered immune to measles and 
mumps. All adults born in 1957 or later should have documentation of 1 or 
more doses o f MMR vaccine unless they have a medical contraindication 
to the vaccine, or laboratory evidence of immunity to each of the three 
diseases. Documentation of provider-diagnosed disease is not considered 
acceptable evidence o f immunity for measles, mumps, or rubella.
Measles component:
• A routine second dose o f MMR vaccine, administered a minimum o f 28 
days after the first dose, is recommended for adults who
—  are students in postsecondary educational institutions;
—  work in a health-care facility; or
—  plan to travel internationally.
• Persons who received inactivated (killed) measles vaccine or measles vac­
cine of unknown type during 1963-1967 should be revaccinated with 2 
doses of MMR vaccine.
Mumps component:
• A routine second dose o f MMR vaccine, administered a minimum o f 28 
days after the first dose, is recommended for adults who
—  are students in a postsecondary educational institution;
—  work in a health-care facility; or
—  plan to travel internationally.
• Persons vaccinated before 1979 w ith either killed mumps vaccine or 
mumps vaccine of unknown type who are at high risk for mumps infec­
tion (e.g., persons who are working in a health-care facility) should be 
considered for revaccination with 2 doses o f MMR vaccine.
Rubella component:
• For women of childbearing age, regardless o f birth year, rubella immunity 
should be determined. If there is no evidence of immunity, women who 
are not pregnant should be vaccinated. Pregnant women who do not have 
evidence of immunity should receive MMR vaccine upon completion or 
termination of pregnancy and before discharge from the health-care facility.
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HCP born before 1957:
• For unvaccinated health-care personnel born before 1957 who lack labora­
tory evidence of measles, mumps, and/or rubella immunity or laboratory 
confirmation of disease, health-care facilities should consider vaccinating 
personnel with 2 doses of MMR vaccine at the appropriate interval for 
measles and mumps or 1 dose of MMR vaccine for rubella.
8. Pneumococcal polysaccharide (PPSV23) vaccination
• Vaccinate all persons with the following indications:
— all adults aged 65 years and older;
— adults younger than age 65 years with chronic lung disease (including 
chronic obstructive pulmonary disease, emphysema, and asthma); 
chronic cardiovascular diseases; diabetes mellitus; chronic renal fail­
ure; nephrotic syndrome; chronic liver disease (including cirrhosis); 
alcoholism; cochlear implants; cerebrospinal fluid leaks; immunocom­
promising conditions; and functional or anatomic asplenia (e.g., sickle 
cell disease and other hemoglobinopathies, congenital or acquired 
asplenia, splenic dysfunction, or splenectomy [if elective splenectomy 
is planned, vaccinate at least 2 weeks before surgery]);
—  residents of nursing homes or long-term care facilities; and
—  adults who smoke cigarettes.
• Persons with immunocompromising conditions and other selected con­
ditions are recommended to receive PCV13 and PPSV23 vaccines. See 
footnote #10 for information on tim ing of PCV13 and PPSV23 vaccinations.
• Persons with asymptomatic or symptomatic HIV infection should be vac­
cinated as soon as possible after their diagnosis.
• When cancer chemotherapy or other immunosuppressive therapy is 
being considered, the interval between vaccination and in itiation of 
immunosuppressive therapy should be at least 2 weeks. Vaccination during 
chemotherapy or radiation therapy should be avoided.
• Routine use of PPSV23 is not recommended for American Indians/Alaska 
Natives or other persons younger than age 65 years unless they have 
underlying medical conditions that are PPSV23 indications. However, pub­
lic health authorities may consider recommending PPSV23 for American 
Indians/Alaska Natives who are living in areas where the risk for invasive 
pneumococcal disease is increased.
• When indicated, PPSV23 should be administered to patients who are 
uncertain o f their vaccination status and there is no record o f previous 
vaccination. When PCV13 is also indicated, a dose of PCV13 should be 
given first (see footnote #10).
9. Revaccination with PPSV23
• One-time revaccination 5 years after the first dose is recommended for 
persons aged 19 through 64 years with chronic renal failure or nephrotic 
syndrome; functional or anatomic asplenia (e.g., sickle cell disease or 
splenectomy); and for persons with immunocompromising conditions.
• Persons who received 1 or 2 doses of PPSV23 before age 65 years for any 
indication should receive another dose of the vaccine at age 65 years or 
later if at least 5 years have passed since their previous dose.
• No further doses are needed for persons vaccinated with PPSV23 at or after 
age 65 years.
10. Pneumococcal conjugate 13-valent vaccination (PCV13)
• Adults aged 19 years or older w ith immunocompromising conditions 
(including chronic renal failure and nephrotic syndrome), functional or 
anatomic asplenia, CSF leaks or cochlear implants, and who have not pre­
viously received PCV13 or PPSV23 should receive a single dose of PCV13 
followed by a dose of PPSV23 at least 8 weeks later.
• Adults aged 19 years or older with the aforementioned conditions who 
have previously received one or more doses of PPSV23 should receive a 
dose of PCV13 one or more years after the last PPSV23 dose was received. 
For those that require additional doses of PPSV23, the first such dose should 
be given no sooner than 8 weeks after PCV13 and at least 5 years since the 
most recent dose o f PPSV23.
• When indicated, PCV13 should be administered to patients who are uncer­
tain of their vaccination status history and there is no record of previous 
vaccination.
• Although PCV13 is licensed by the Food and Drug Administration (FDA) 
for use among and can be administered to persons aged 50 years and 
older, ACIP recommends PCV13 for adults aged 19 years and older with 
the specific medical conditions noted above.
11. Meningococcal vaccination
• Administer 2 doses of meningococcal conjugate vaccine quadrivalent 
(MCV4) at least 2 months apart to adults with functional asplenia or per­
sistent complement component deficiencies.
• HIV-infected persons who are vaccinated also should receive 2 doses.
• Administer a single dose o f meningococcal vaccine to microbiologists 
routinely exposed to isolates of Neisseria m en ing itid is , military recruits, and 
persons who travel to or live in countries in which meningococcal disease 
is hyperendemic or epidemic.
• First-year college students up through age 21 years who are living in 
residence halls should be vaccinated if they have not received a dose on 
or after their 16th birthday.
• MCV4 is preferred for adults with any of the preceding indications who 
are aged 55 years and younger; meningococcal polysaccharide vaccine 
(MPSV4) is preferred for adults aged 56 years and older.
• Revaccination with MCV4 every 5 years is recommended for adults previ­
ously vaccinated with MCV4 or MPSV4 who remain at increased risk for 
infection (e.g., adults with anatomic or functional asplenia or persistent 
complement component deficiencies).
12. Hepatitis A vaccination
• Vaccinate any person seeking protection from hepatitis A virus (HAV) 
infection and persons with any of the following indications:
—  men who have sex with men and persons who use injection or non­
injection illicit drugs;
—  persons working with HAV-infected primates or with HAV in a research 
laboratory setting;
—  persons with chronic liver disease and persons who receive clotting 
factor concentrates;
—  persons traveling to or working in countries that have high or inter­
mediate endemicity o f hepatitis A; and
—  unvaccinated persons who anticipate close personal contact (e.g., 
household or regular babysitting) w ith an international adoptee dur­
ing the first 60 days after arrival in the United States from a country 
with high or intermediate endemicity. (See footnote #1 for more 
information on travel recommendations). The first dose o f the 2-dose 
hepatitis A vaccine series should be administered as soon as adoption 
is planned, ideally 2 or more weeks before the arrival o f the adoptee.
• Single-antigen vaccine formulations should be administered in a 2-dose 
schedule at either 0 and 6-12 months (Havrix), or 0 and 6-18 
months (Vaqta). If the combined hepatitis A and hepatitis B vaccine 
(Twinrix) is used, administer 3 doses at 0, 1, and 6 months; alternatively, 
a 4-dose schedule may be used, administered on days 0, 7, and 21-30, 
followed by a booster dose at month 12.
13. Hepatitis B vaccination
• Vaccinate persons with any of the following indications and any person 
seeking protection from hepatitis B virus (HBV) infection:
—  sexually active persons who are not in a long-term, mutually monoga­
mous relationship (e.g., persons with more than one sex partner during 
the previous 6 months); persons seeking evaluation or treatment for 
a sexually transmitted disease (STD); current or recent injection-drug 
users; and men who have sex with men;
—  health-care personnel and public-safety workers who are potentially 
exposed to blood or other infectious body fluids;
—  persons with diabetes younger than age 60 years as soon as feasible 
after diagnosis; persons with diabetes who are age 60 years or older 
at the discretion o f the treating clinician based on increased need for 
assisted blood glucose monitoring in long-term care facilities, likeli­
hood o f acquiring hepatitis B infection, its complications or chronic 
sequelae, and likelihood of immune response to vaccination;
—  persons with end-stage renal disease, including patients receiving 
hemodialysis; persons with HIV infection; and persons with chronic 
liver disease;
—  household contacts and sex partners of hepatitis B surface antigen­
positive persons; clients and staff members o f institutions for per­
sons w ith developmental disabilities; and international travelers 
to countries with high or intermediate prevalence o f chronic HBV 
infection; and
—  all adults in the following settings: STD treatment facilities; HIV test­
ing and treatment facilities; facilities providing drug-abuse treatment 
and prevention services; health-care settings targeting services to 
injection-drug users or men who have sex with men; correctional 
facilities; end-stage renal disease programs and facilities for chronic 
hemodialysis patients; and institutions and nonresidential daycare 
facilities for persons with developmental disabilities.
• Administer missing doses to complete a 3-dose series of hepatitis B vaccine 
to those persons not vaccinated or not completely vaccinated. The second
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dose should be administered 1 month after the first dose; the third dose 
should be given at least 2 months after the second dose (and at least 4 
months after the first dose). If the combined hepatitis A and hepatitis B 
vaccine (Twinrix) is used, give 3 doses at 0, 1, and 6 months; alternatively, 
a 4-dose Twinrix schedule, administered on days 0, 7, and 21-30 followed 
by a booster dose at month 12 may be used.
• Adult patients receiving hemodialysis or with other immunocompromising 
conditions should receive 1 dose of 40 pg/mL (Recombivax HB) adminis­
tered on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 ^g/mL 
(Engerix-B) administered simultaneously on a 4-dose schedule at 0, 1, 2, 
and 6 months.
14. Selected conditions for which Haemophilus influenzae type b (Hib) vac­
cine may be used
• 1 dose o f Hib vaccine should be considered for persons who have sickle 
cell disease, leukemia, or HIV infection, or who have anatomic or functional 
asplenia if they have not previously received Hib vaccine.
15. Immunocompromising conditions
• Inactivated vaccines generally are acceptable (e.g., pneumococcal, 
meningococcal, and influenza [inactivated influenza vaccine]), and live 
vaccines generally are avoided in persons with immune deficiencies or 
immunocompromising conditions. Information on specific conditions is 
available at http://www.cdc.gov/vaccines/pubs/acip-list.htm.
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TABLE. Contraindications and precautions to commonly used vaccines in adults1*"*
Vaccine Contraindications Precautions
Influenza, inactivated vaccine (IIV) Severe allergic reaction (e.g., anaphylaxis) after 
previous dose of any influenza vaccine or to a 
vaccine component, including egg protein.
Moderate or severe acute illness with or w ithout fever.
History of Guillain-Barré Syndrome (GBS) within 6 weeks of 
previous influenza vaccination.
Persons who experience only hives with exposure to eggs should 
receive IIV with additional safety precautions.2
Influenza, live attenuated (LAIV)3 Severe allergic reaction (e.g., anaphylaxis) after 
previous dose of any influenza vaccine or to a 
vaccine component, including egg protein. 
Conditions for which the Advisory Committee 
on Immunization Practices (ACIP) recommends 
against use, but which are not contraindications 
in vaccine package insert: immune suppression, 
certain chronic medical conditions such as 
asthma, diabetes, heart or kidney disease. and 
pregnancy.4
Moderate or severe acute illness with or w ithout fever.
History of GBS within 6 weeks o f previous influenza vaccination. 
Receipt o f specific antivirals (i.e., amantadine, rimantadine, 
zanamivir, or oseltamivir) 48 hours before vaccination. Avoid use of 
these antiviral drugs for 14 days after vaccination.
Tetanus, diphtheria, pertussis (Tdap); 
tetanus, diphtheria (Td)
Severe allergic reaction (e.g., anaphylaxis) after a 
previous dose or to a vaccine component.
For pertussis-containing vaccines: 
encephalopathy (e.g., coma, decreased level 
o f consciousness, or prolonged seizures) not 
attributable to another identifiable cause 
within 7 days of administration o f a previous 
dose of Tdap or diphtheria and tetanus toxoids 
and pertussis (DTP) or diphtheria and tetanus 
toxoids and acellular pertussis (DTaP) vaccine.
Moderate or severe acute illness with or w ithout fever.
GBS within 6 weeks after a previous dose o f tetanus toxoid- 
containing vaccine.
History of arthus-type hypersensitivity reactions after a previous 
dose of tetanus or diptheria toxoid-containing vaccine; defer 
vaccination until at least 10 years have elapsed since the last 
tetanus toxoid-containing vaccine.
For pertussis-containing vaccines: progressive or unstable 
neurologic disorder, uncontrolled seizures, or progressive 
encephalopathy until a treatment regimen has been established 
and the condition has stabilized.
Varicella2 Severe allergic reaction (e.g., anaphylaxis) after a 
previous dose or to a vaccine component. 
Known severe immunodeficiency (e.g., from 
hematologic and solid tumors, receipt of 
chemotherapy, congenital immunodeficiency, 
or long-term immunosuppressive therapy5 
or patients w ith human immunodeficiency 
virus (HIV) infection who are severely 
immunocompromised).
Pregnancy.
Recent (within 11 months) receipt o f antibody-containing blood 
product (specific interval depends on product).6,7 
Moderate or severe acute illness with or w ithout fever.
Receipt o f specific antivirals (i.e., acyclovir, famciclovir, or 
valacyclovir) 24 hours before vaccination; avoid use of these 
antiviral drugs for 14 days after vaccination.
Human papillomavirus (HPV) Severe allergic reaction (e.g., anaphylaxis) after a 
previous dose or to a vaccine component.
Moderate or severe acute illness with or w ithout fever. 
Pregnancy.
Zoster Severe allergic reaction (e.g., anaphylaxis) to a 
vaccine component.
Known severe immunodeficiency (e.g., 
from hematologic and solid tumors, 
receipt o f chemotherapy, or long-term 
immunosuppressive therapy5 or patients 
with HIV infection who are severely 
immunocompromised).
Pregnancy.
Moderate or severe acute illness with or w ithout fever. 
Receipt o f specific antivirals (i.e., acyclovir, famciclovir, or 
valacyclovir) 24 hours before vaccination; avoid use of these 
antiviral drugs for 14 days after vaccination.
Measles, mumps, rubella (MMR)3 Severe allergic reaction (e.g., anaphylaxis) after a 
previous dose or to a vaccine component. 
Known severe immunodeficiency (e.g., from 
hematologic and solid tumors, receipt of 
chemotherapy, congenital immunodeficiency, 
or long-term immunosuppressive therapy5 or 
patients with HIV infection who are severely 
immunocompromised).
Pregnancy.
Moderate or severe acute illness with or w ithout fever.
Recent (within 11 months) receipt o f antibody-containing blood 
product (specific interval depends on product).6,7 
History of thrombocytopenia or thrombocytopenic purpura. 
Need for tuberculin skin testing.8
See footnotes on page 18.
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TABLE. (Continued) Contraindications and precautions to commonly used vaccines in adults1*"*
Vaccine Contraindications Precautions
Pneumococcal polysaccharide (PPSV) Severe allergic reaction (e.g., anaphylaxis) after a 
previous dose or to a vaccine component.
Moderate or severe acute illness with or w ithout fever.
Pneumococcal conjugate (PCV13) Severe allergic reaction (e.g., anaphylaxis) after 
a previous dose or to a vaccine component, 
including to any vaccine containing diphtheria 
toxoid.
Moderate or severe acute illness with or w ithout fever.
Meningococcal, conjugate, (MCV4); 
meningococcal, polysaccharide (MPSV4)
Severe allergic reaction (e.g., anaphylaxis) after a 
previous dose or to a vaccine component.
Moderate or severe acute illness with or w ithout fever.
Hepatitis A (HepA) Severe allergic reaction (e.g., anaphylaxis) after a 
previous dose or to a vaccine component.
Moderate or severe acute illness with or w ithout fever.
Hepatitis B (HepB) Severe allergic reaction (e.g., anaphylaxis) after a 
previous dose or to a vaccine component.
Moderate or severe acute illness with or w ithout fever.
1. Vaccine package inserts and the full ACIP recommendations for these vaccines should be consulted for additional information on vaccine-related contraindications 
and precautions and for more information on vaccine excipients. Events or conditions listed as precautions should be reviewed carefully. Benefits o f and risks for 
administering a specific vaccine to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the 
vaccine should not be administered. If the benefit o f vaccination is believed to outweigh the risk, the vaccine should be administered. A contraindication is a 
condition in a recipient that increases the chance of a serious adverse reaction. Therefore, a vaccine should not be administered when a contraindication is present.
2. CDC. Prevention and control o f influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2012-13 
influenza season. MMWR 2012;61:613-8.
3. LAIV, MMR, and varicella vaccines can be administered on the same day. If not administered on the same day, these live vaccines should be separated by at least 
28 days.
4. For a complete list o f conditions that CDC considers to be reasons to avoid getting LAIV, see CDC. Prevention and control of influenza with vaccines: recommendations 
o f the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59(No. RR-8). Available at http://www.cdc.gov/vaccines/pubs/acip-list.htm.
5. Immunosuppressive steroid dose is considered to be 2 or more weeks of daily receipt o f 20 mg prednisone or the equivalent. Vaccination should be deferred for 
at least 1 month after discontinuation of such therapy. Providers should consult ACIP recommendations for complete information on the use of specific live vaccines 
among persons on immune-suppressing medications or with immune suppression because of other reasons.
6. Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered.
7. See CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(No. RR-2). 
Available at http://www.cdc.gov/vaccines/pubs/acip-list.htm.
8. Measles vaccination might suppress tuberculin reactivity temporarily. Measles-containing vaccine may be administered on the same day as tuberculin skin testing. 
If testing cannot be performed until after the day o f m Mr vaccination, the test should be postponed for at least 4 weeks after the vaccination. If an urgent need 
exists to skin test, do so with the understanding that reactivity might be reduced by the vaccine.
* Adapted from CDC. Table 6. Contraindications and precautions to commonly used vaccines. General recommendations on immunization: recommendations o f the 
Advisory Committee on Immunization Practices. MMWR 2011;60(No. RR-2):40-41 and from Atkinson W, Wolfe S, Hamborsky J, eds. Appendix A. Epidemiology and 
prevention of vaccine preventable diseases. 12th ed. Washington, DC: Public Health Foundation, 2011. Available at http://www.cdc.gov/vaccines/pubs/pinkbook/ 
index.html.
f  Regarding latex allergy. Consult the package insert for any vaccine administered.
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